Johnson Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.

Food and Healthcare Press Releases Wednesday June 13, 2018 08:00
NEW BRUNSWICK, New Jersey--13 Jun--PRNewswire/InfoQuest

Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch(R) brand of products.

This acceptance was made after consultation with relevant works councils and trade unions. The transaction is expected to close by the end of 2018, subject to the satisfaction of regulatory clearances and other customary closing conditions.

The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses. These include important leadership and innovation in areas such as bariatric surgery and through medicines such as INVOKANA(R) (canagliflozin) and INVOKAMET(R) (canagliflozin/metformin HCl).

About LifeScan

LifeScan, Inc. is a world leader in blood glucose monitoring. In the U.S., LifeScan, Inc. is the leading maker of blood glucose monitoring systems and its OneTouch(R) brand products are recommended by more endocrinologists and primary care physicians than any other brand.[1] Globally, more than 20 million people depend on OneTouch(R) brand products for simple testing and accurate results to help them manage their diabetes. For more information visit: www.OneTouch.com .

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Note on Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to the divestiture of the LifeScan business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the possibility that the transaction will not be completed, or if completed, not completed in the expected timeframe, and the potential that the expected strategic benefits or opportunities from any divestiture may not be realized, or may take longer to realize than expected. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

[1] Global Brand Equity Insights Study, February 2015

Latest Press Release

Venus Medtech Enters North American Market

- First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada On June 12, 2018, St Paul 's Hospital in Vancouver, Canada successfully completed two cases of VenusP-Valve...

What You Think About Getting Old Impacts Your Health, Quality of Life According to New Orb Media Reporting

New Orb Media Inc. reporting and data analysis [ https://www.orbmedia.org/agewell ] shows a strong connection between how we view old age, how well we age and the effects seen across world cultures. Individuals with a positive attitude towards old age...

Johnson Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.

Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in...

KTC in association with Bangkok Hospital give a talk on Minimally Invasive Surgery and offer a package of Ovarian and Uterine Cancer Screening.

"KTC" or Krungthai Card Public Company Limited by Ms. Sireerat Corvanich, Vice President - Credit Card Business, sees the importance of health care for women especially with pelvic examination, therefore in association with Women Health Center of Bangkok...

Joint Commission International Appoints New Leadership in Key Strategic Region

Joint Commission International (JCI) is pleased to announce John Yoon, MBA , as JCI's managing director of the Asia-Pacific Region. In this role, he is responsible for developing relationships between JCI and health care organizations, governments,...

Related Topics